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        Introduction
 
● Traumatic Brain Injury (TBI) is the leading cause of death and disability 
for people under 35 and over 65 in the United States. 
● There are currently no approved pharmaceutical treatments for TBI, 
which represents a major unmet need.
● Recent statistics show there were about 2.5 million TBI-related 
emergency department (ED) visits, 282,000 hospitalizations, and 56,000 
deaths in the United States.
● The total economic burden of TBI in 2017, including direct and indirect 
medical costs, is estimated at $86 billion. 
● If the injury is not fatal, the extent of swelling in the brain (edema) is 
strongly associated with long lasting damage due to cytotoxic edema. In 
vivo studies show moderate and severe TBI disrupts the Blood Brain 
Barrier (BBB) which causes a surge in arginine vasopressin (AVP) 
secretion, a hormone concerned with water permeability and ion 
homeostasis. 
● The increased exposure of cells to vasopressin leads to dysregulation of 
AQP4, a water channel protein found in the brain, which is strongly 
implicated in cytotoxic edema. 
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1. In vitro regulation of AQP4 for the development of a rapid drug screening system
Organotypic Culture
• Mice were sacrificed and the brains were sectioned into 500 
micrometer slices.  
• Slices were divided along the midline to the left and right halves.
Western Blot
• an analytical technique to detect specific proteins 
2. Improved design and production of a momentum exchange device for inducing 
TBI in vivo
Optimizing Culture Conditions for Western Blots: AQP4 expression in the 
presence or absence of serum-free media 
● The momentum exchange device delivers a controlled impact to the 
head of an anesthetized rat. It was first developed by Viano and 
co-workers. 
● This model is advantageous because after impact, it allows for 
movement of the head and neck.  This mimics impact conditions in 
human TBI. 
● Objective was to design an improved momentum exchange device. This 
was done in collaboration with mechanical engineers.  
● Enhancements include:
○ Added degrees of freedom in the movement of animal after impact
○ Multi-axial accelerometry
         samples without serum                              samples with 20% serum
Results: Expression of AQP4 is higher in serum-containing conditions rather than 
serum-free conditions 
30 KD AQP4
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       Future Directions
● Conduct time and dosage dependent experiments with multiple V1a 
antagonists in our organotypic culture conditions.  
● Calibrate the momentum-exchange device using ballistic gels to simulate 
tissue impact. 
● Screen V1a receptor antagonists in vitro for their effect on AQP4 and in 
vivo for effects on cerebral edema and cognitive functions.
● Test for TBI biomarkers including: Glial Fibrillary Acidic Protein 
(GFAP), Ubiquitin C-Terminal Hydrolase L1 (UCHL1), and S100B. 
These serum markers are currently used in clinical settings.  
● Use the results to identify promising candidates for clinical development 
for the treatment of moderate and severe TBI.  
   Progress
● We have identified higher production of AQP4 in slices containing 20% serum than 
serum-free slices
● ~5 hour incubation time may be optimal for assessing AQP4 regulation
● We previously found that five days of treatment with a highly selective V1a receptor 
antagonist that crosses the BBB:
○ significantly reduced cerebral edema 
○ eliminated cognitive deficits  
 Hypothesis
● Antagonism of V1a receptor will reduce or block the upregulation of AQP4, 
thus reducing post-TBI cerebral edema.
 
  Novel Object Time Novel Object Index
Novel Object
Encounters
AVN576 HIT HIT + AVN576
Cognitive Behavior: Novel Object Recognition*
* tests episodic learning and memory-related stimulus recognition
V1a Antagonist Treatment for 5 Days Controls Post-Concussion Edema in 
Lateral Ventricles
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Progress
●         A prototype has of the momentum exchange device has been built
